Personalized Therapy Biosimulation Market Size to Reach USD 3,164.1 Million in 2028 Growing at a CAGR of 14.6%, according to Emergen Research

Emergen Research has published its latest report titled “Personalized Therapy Biosimulation Market, By Product Type (Software, Services), By Therapeutic Area (Oncology, Others), By Application (Drug Development, Drug Discovery, Others), By Delivery Model (Subscription Models, Ownership Models), By End-use (Pharmaceutical and Biotechnology Companies, Research Centers & Academic Institutes, Contract Research Organizations, Others), and By Region, Forecast to 2028”

According to Emergen Research, the global personalized therapy biosimulation market size was USD 1,061.7 million in 2020 and is expected to reach USD 3,164.1 million in 2028 and register a revenue CAGR of 14.6% during the forecast period, 2021-2028.

Market Dynamics:

The global personalized therapy biosimulation market revenue growth is majorly supported by factors such as increasing cases of drug relapse and drug resistance, rising prevalence of severe chronic diseases such as cancer, rising focus on developing personalized cancer therapies, and increasing investments by government bodies in pharmaceutical and biotechnology R&D activities for advanced therapeutics. Growing use of biologics and biosimilars due to growing need for decreasing R&D costs and better safety and efficacy in clinical trials is another key factor driving the global personalized therapy biosimulation market revenue growth to a major extent.

In personalized therapy biosimulation, computational models are used to describe various pharmacokinetic, biological, and pathological processes to facilitate drug development. Through this process, a multi-omic profile of the patient is created that helps predict individual patient responses to particular drug combinations. Leading prediction medicine company, Cellwork Group Inc., has introduced a personalized cancer therapy biosimulation platform that leverages biosimulation technology, artificial intelligence, next-generation sequencing (NGS) informatics, and therapy response index (TRI) to improve cancer treatments and enhance patient care. Furthermore, continuous advancements in precision oncology and growing use of Quantitative System Pharmacology (QSP) in drug discovery & development processes are factors expected to drive market revenue growth in the near future.

Click Here to Access Free sample PDF Copy of the Report@ https://www.emergenresearch.com/request-sample/785

 COVID-19 Impact Analysis:

  • Social distancing and restrictions severely disrupted businesses and operations
  • Lockdowns caused disruptions in transportation and logistics
  • Impacted manufacturing activities and mining operations globally
  • Took a toll on economy of various countries
  • Caused sudden and drastic downturn in economic activity
  • Disrupted agriculture, fisheries, dairy, and other sectors
  • Caused loss of employment and financial crisis
  • Supply impacts were further compounded owing to reduced disposable income
  • Emergence of variants  continue to cause concerns and impact normal routines

Drug Development Segment Accounted for Largest Revenue Share in 2020:

The drug development segment dominated other application segments in terms of revenue share in the global market in 2020. Growing use of advanced biosimulation technologies in drug development processes – which include investigation of new drugs, preclinical testing, and clinical testing, rising need to streamline clinical trial processes, and increasing applications of pharmacokinetics/pharmacodynamics (PK/PD) modelling and simulation techniques are major factors driving revenue growth of this segment.

Pharmaceutical and Biotechnology Companies Segment to Account for Fastest Revenue CAGR:

The pharmaceutical & biotechnology companies segment is projected to register the fastest revenue CAGR over the forecast period, owing to factors such as rise in pharmaceutical R&D activities, increasing clinical studies and trials of new drugs to determine their safety and efficacy, growing use of advanced biosimulation techniques in drug development, and increasing need for advanced cancer therapeutics.

North America Accounted for Largest Revenue Share in 2020:

North America account for largest revenue share in the global market in 2020. Rise in pharmaceutical research and development programs, rapid adoption of cutting-edge, AI-based biosimulation technologies to facilitate drug discovery and development, rising number of clinical trials of new drugs and therapeutics, and growing prevalence of chronic diseases such as cancer are among the major factors contributing to the North America market revenue growth. Other factors such as rising demand for personalized cancer therapy, increasing applications of QSP in pharmaceutical R&D activities, and presence of key market players including Certara USA Inc., Nuventra Pharma, and Cellworks Group Inc. in the region further boost the regional market revenue growth.

Make Payment [Buy your Exclusive copy]@ https://www.emergenresearch.com/select-license/785

Major Companies in the Global Personalized Therapy Biosimulation Market Include:

  • Cellworks Group Inc.
  • Certara USA Inc.
  • Simulation Plus Inc.
  • In Silico Biosciences Inc.
  • Genedata AG
  • Physiomics plc
  • Insilico Biotechology AG
  • Chemical Computing Group ULC (CCG)
  • Evidera Inc.
  • Dassault Systèmes
  • Nuventra Pharma
  • Schrödinger Inc.
  • ACD/Labs
  • INOSIM Software
  • LeadInvent Technologies

For the purpose of this report, Emergen Research has segmented the personalized therapy biosimulation market based on product type, therapeutic area, application, delivery model, end-use, and region:

Product Type Outlook (Revenue, USD Million; 2018–2028)

  • Software
  • Services

Therapeutic Area Outlook (Revenue, USD Million; 2018–2028)

  • Oncology
  • Others

Application Outlook (Revenue, USD Million; 2018–2028)

  • Drug Development
  • Preclinical Testing
  • PK/PD
  • ADME/TOX
  • Clinical Trials
  • Drug Discovery
  • Target Identification and Validation
  • Lead Identification and Optimization
  • Others

Delivery Model Outlook (Revenue, USD Million; 2018–2028)

  • Subscription Models
  • Ownership Models

End-use Outlook (Revenue, USD Million; 2018–2028)

  • Pharmaceutical and Biotechnology Companies
  • Research Centers & Academic Institutes
  • Contract Research Organizations (CROs)
  • Others

Have a look at Report Description and Table of Contents of Market Report@ https://www.emergenresearch.com/industry-report/personalized-therapy-biosimulation-market

Region Outlook (Revenue, USD Million; 2018-2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Turkey
    • Rest of Middle East & Africa

Explore Reports offered by Emergen Research:

Antibody-Drug Conjugates (ADC) Market size is expected to reach USD 20.01 Billion in 2028 and register a CAGR of 25.8% during the forecast period. Increasing prevalence of cancer and rapidly increasing geriatric population are some of the key factors driving global antibody-drug conjugates market revenue growth.

Nanorobotics market size is expected to reach USD 14.03 Billion in 2028 and register a CAGR of 10.9% during the forecast period. Steady global nanorobotics market revenue growth can be attributed to various innovations in nanorobotics technology and its rising application in treatment of neurological, cardiovascular, oncological, infectious, and orthopedic diseases, and others.

Implantable cardioverter defibrillator market size is expected to reach USD 8.81 Billion in 2028 and register a CAGR of 2.7% during the forecast period. Global implantable cardioverter defibrillator market revenue growth is driven by increasing prevalence of cardiovascular diseases and rising associated conditions and diseases and risks arising from obesity and sedentary lifestyle.

Single use/disposable endoscopy market size reached USD 1.35 Billion in 2020 and is expected to reach USD 6.29 Billion in 2028 and register a CAGR of 21.1% during the forecast period. A major factor driving market revenue growth is increasing prevalence of chronic and infectious diseases and lifestyle-related health conditions, and digestive system diseases among an increasing patient pool of varying age groups.

Oncolytic virus therapies market size is expected to reach USD 609.7 Million in 2028 and register a CAGR of 26.2% during the forecast period. Rise in prevalence of cancer, increase in number of clinical trials and investment in research & development for cancer therapies are driving the growth of oncolytic virus therapies market.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkdIn | Twitter | Blogs

Full Press Release@ https://www.emergenresearch.com/press-release/global-personalized-therapy-biosimulation-market

Back to news